CRISPR CAR Therapy Shows 100% ORR in NHL in Chinese Trial

News
Article

BRL Medicine is also enrolling a phase 1/2 multicenter trial evaluating BRL-201 at lower dose ranges.

 Biao Zheng, PhD

Biao Zheng, PhD

BRL-201 CRISPR-/Cas9-based chimeric antigen receptor (CAR) T-cell therapy yielded a 100% overall response rate (ORR) in 21 patients with relapsed/refractory (r/r) non-Hodgkin lymphoma treated in a phase 1/2 clinical trial in China (NCT04213469).

Data from the trial, updated as of May 2023, were presented at The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, held November 1-5 in San Diego, California, by Biao Zheng, PhD, chief executive officer, BRL Medicine.

“Unlike current viral-based or transposon-based CAR T-cells in which integration occurs randomly and with various copy numbers, yielding a very heterogenous CAR T population, in our approach, the CAR sequence precisely integrates into the PD-1 site, so you can generate a very homogenous population. [This approach] has shown a great efficacy and safety profile in earlier and ongoing clinical trials,” Zheng said during his presentation.

The trial’s primary endpoint is the incidence of dose-limiting toxicities, and its secondary endpoint is the ORR at 3 months with the CD19-targeting CAR T-cell therapy. The trial treated patients with diffuse large B-cell lymphoma (DLBCL; n = 17), mantle cell lymphoma (n = 2); B-cell lymphoblastic lymphoma (B-LBL; n = 1), and follicular lymphoma (n = 1). These participants had a median age of 56 years (range, 34–70) and a median of 4 prior lines of therapy (range, 1–9). Seventeen (93.8%) were diagnosed with disease stage 3 or 4, and 13 patients (81.3%) were assessed with intermediate to high risk according to International Prognostic Index (IPI) or age-adjusted IPI scores.

READ MORE: A2 Bio’s Screening Study Identifies Eligible Patients for Treatment With Tmod CAR-T

The participants underwent leukapheresis and lymphodepletion chemotherapy with cyclophosphamide and fludarabine before infusion of dose escalating 2×106/kg (n = 12), 4×106/kg (n = 3), or 6×106/kg (n = 3) BRL-201. Three patients received 0.56 to 0.8x106/kg cells.

As of the data cutoff date, median follow-up was 29.0 months (range, 21.5-36.2) and all patients responded to BRL-201 treatment. Most patients (n = 18, 85.7%) had a complete response (CR), 7 of which have maintained a CR. The median duration of response was 15.1 months (95% CI, 5.9 - not applicable [NA]), median progression free survival was 20.8 months (95% CI, 8.2-NA), and median overall survival (OS) was not reached. Twelve-month OS rate was 76.2% (95% CI, 60-96.8).

By dose level, CR rate was 83.3% (2×106/kg), 66.7% (4×106/kg), 100% (6×106/kg), and 100% (0.56-0.8 ×106/kg). By disease, CR rate was 100% in patients with MCL, B-LBL, and FL, and was 82.4% in patients with DLBCL. During his presentation, Zheng pointed out that BRL-201 induced enduring, continuing CRs in 3 of 4 patients with PD-L1 expression over 50%.

In terms of safety, over half (n = 14; 66.7%) of patients experienced grades 1-to-2 cytokine release syndrome (CRS) and 1 patient received tocilizumab. Four patients experienced mild grades 1-to-2 immune effector cell-associated neurotoxicity syndrome (ICANS) and no patients experienced serious grade CRS or ICANS.

“BRL-201 is a CD19-targeting CAR T-cell product with nonviral, site-specific integrated CAR-T that aims to reduce potential risk of virus usage, to simplify the manufacture process, and to decrease the expense... of CAR T-cell manufacture,” Zheng said. “Currently, to evaluate BRL-201 antitumor activity at lower dose ranges, a phase 1/2 clinical trial (NCT05741359) is ongoing with a larger scale, multicenter design.”

Click here to read more coverage of the 2023 SITC meeting.

REFERENCE
Zhang B, Hu Y, Zhang J, et al. High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study. Presented at: SITC 38th Annual Meeting; November 1-5, 2023; San Diego, California. Abstract 690.
Related Videos
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Abhishek Gupta, BS, the senior vice president of genetic medicines at Syneos Health
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
© 2024 MJH Life Sciences

All rights reserved.